The First US Tinnitus Guideline Update Since 2014 Names Bimodal Neuromodulation, Handing Neuromod’s Lenire a Coverage Argument
A guideline listing is the first thing a payer asks a device maker for, and Neuromod’s Lenire now has one in tinnitus.
Quick
The daily shorts. One story, one insight.
AbbVie’s Skyrizi Combination Nearly Doubled Endoscopic Remission at 24 Weeks in Crohn’s, in an Open-Label Study Without Placebo
The gap over Skyrizi widened from week 12 to week 24, the stronger signal in an open-label study without placebo.
Germany Added 2.5 Million Women to Mammography Screening While Reopening Skin Cancer Screening After a Proposal to Suspend It
Germany is widening cancer screening where the evidence is settled and reopening it where cost is the question.
Roche’s Hansoh ADC Deal Is Worth Over $15.5 Billion, With $400 Million Upfront for Programmes Still in the Lab
Roche is paying platform money for ADCs that do not exist yet, five times what it paid Hansoh for a clinical asset in 2025.
The FTC Warned 24 Large Healthcare Companies That Following CMS Price Rules Is No Shield Against a Deception Case
A hospital can meet every CMS posting rule and still face an FTC deception case over the estimate a patient receives.
CMS Set December 2027 for Insurers’ Prescription Drug Price Files, a Requirement on Hold Since 2021
The drug file reaches manufacturers, and the schema due around May 2027 decides how much net price becomes public.
Only one Member State was assessing each valve when Brussels chose them, so the joint report will frame the evidence.
Only one Member State was assessing each valve when Brussels chose them, so the joint report will frame the evidence.
Korea’s First Homegrown GLP-1 Cut Weight 9.75% at 40 Weeks, So Hanmi Will Fight Wegovy and Mounjaro on Price and Supply
Hanmi’s GLP-1 trails Wegovy and Mounjaro on weight loss, so its case rests on a low starting price and Korean supply.
Denmark Said No to a DKK 2.5m CAR-T in January and Yes Once Kite Tied the Price to Response
Denmark turned a January no on Tecartus into a yes by tying price to response, and renewed burosumab on a lower price.
ICER Says AstraZeneca’s $10,950 Baxfendy Is Worth $1,400 to $2,500 a Year
ICER has handed payers the case for putting Baxfendy behind generics, and Mineralys gets its price anchor before launch.